I note that:
a) in April 2009 presentation PRR was referring to a 340 patient pivotal study. (see slide 10)
b) subsequnet informal disclosures (Alpha Securities, Bioshares) have hinted that Phase III study may be as small as 60 patients.
c) presentation for tonight indicates that Phase IIb study will be 60 patients. No detail of size of Phase III now being provided.
How big will Phase III be?
I also note that they are now talking up the prospects for an early sale / licensing deal. This would be a good result for PRR shareholders. Might get you 30 cents if the wind is blowing the right way?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.3¢ |
Change
0.003(1.04%) |
Mkt cap ! $350.4M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 24.5¢ | 23.8¢ | $179.0K | 745.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 203532 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 423107 | 26 |
View Market Depth
| Last trade - 15.36pm 14/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |